$59.00
Manufacturer: Slovenia
adults Gastroesophageal reflux disease (GERD): treatment of erosive reflux-esophagitis; long-term treatment of patients with cured esophagitis to prevent relapse; symptomatic treatment of gastroesophageal reflux disease (GERD). In combination with appropriate antibacterial drugs for the eradication of Helicobacter pylori: treatment of duodenal ulcer caused by Helicobacter pylori; preventing the recurrence of peptic ulcers in patients with ulcers caused by Helicobacter pylori . Patients requiring long-term use of non-steroidal anti-inflammatory drugs (NSAIDs): healing of stomach ulcers caused by NSAIDs; prevention of gastric and duodenal ulcers caused by NSAIDs in patients at risk. Long-term treatment after intravenous use of the drug to prevent recurrence of bleeding from peptic ulcers.
Description
Emanera Composition
active substance: 1 enteric capsule contains 20 mg or 40 mg of esomeprazole (in the form of esomeprazole magnesium dihydrate)
Emanera excipients: spherical sugar (contains sucrose), povidone, sodium lauryl sulfate, opadray II white 85F28751, magnesium carbonate, methacrylate copolymer dispersion, talc, macrogol 6000, titanium dioxide (E 171), polysorbate 80, iron oxide red (E172), gelatin …
Emanera Dosage form
Enteric capsules.
Pharmacological group
ATC code А02В С05.
Indications
Gastroesophageal reflux disease:
erosive reflux esophagitis treatment
long-term treatment to prevent relapse
symptomatic treatment of gastroesophageal reflux disease.
In combination with antibacterial agents for the eradication of Helicobacter pylori:
treatment of duodenal ulcer associated with Helicobacter pylori
prevention of recurrence of peptic ulcers in patients with ulcers caused by Helicobacter pylori.
Treatment and prevention of ulcers caused by long-term use of non-steroidal anti-inflammatory drugs (NSAIDs):
treating ulcers caused by NSAID therapy
prevention of stomach and duodenal ulcers in patients at risk of taking NSAIDs.
Prevention of recurrent bleeding of gastric or duodenal ulcers after treatment with esomeprazole in the form of an infusion solution.
Treatment of Zollinger-Ellison syndrome.
Contraindications
Hypersensitivity to the active substance, substituted benzimidazole or any other ingredient of the drug.
Age up to 12 years.
Method of administration and dosage
The capsules must be swallowed whole with a liquid. The drug can be taken at any time of the day with or without food. The capsules must not be chewed or crushed.
For patients who find it difficult to swallow, the capsule can be opened and the granules mixed with half a glass of still water. Any other liquid is not recommended for use due to possible damage to the enteric coating of the granules. The liquid with granules should be drunk immediately or within 30 minutes after preparation. After that, you need to rinse the glass with half a glass of water and drink. The granules must not be chewed or crushed.
Adults and children over 12 years old
Gastroesophageal reflux disease
Treatment of erosive reflux esophagitis: 40 mg once a day for 4 weeks. An additional 4 weeks is recommended for patients in whom esophagitis has not healed or whose symptoms persist.
Long-term treatment of relapses in patients with healed esophagitis: 20 mg once a day.
Symptomatic treatment of gastroesophageal reflux disease: 20 mg once a day in patients without esophagitis. If symptom control is not achieved within 4 weeks of treatment, the patient should be evaluated. When symptoms are eliminated, 20 mg once a day may be sufficient for further control. For adults, you can use the “if necessary” regimen, taking 20 mg once a day. Patients who have used NSAIDs and in whom there is a risk of developing gastric or duodenal ulcers, further control of symptoms using the “if necessary” regimen is not recommended.
Recent Reviews